Last reviewed · How we verify
HD IL2
At a glance
| Generic name | HD IL2 |
|---|---|
| Also known as | Proleukin, Aldesleukin |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients (PHASE2)
- Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL (PHASE1)
- Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study (PHASE2)
- High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma (PHASE2)
- Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) (PHASE2)
- Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma (PHASE2)
- The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma (PHASE2)
- Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HD IL2 CI brief — competitive landscape report
- HD IL2 updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI